Merck and AstraZeneca updates on US regulatory review of Lynparza for mCRPC
AstraZeneca and Merck are committed to working with the FDA to bring LYNPARZA in combination with abi/pred to patients diagnosed with mCRPC.
AstraZeneca and Merck are committed to working with the FDA to bring LYNPARZA in combination with abi/pred to patients diagnosed with mCRPC.
Julian Collins, Jana Windt and Michiel Stork join biopharma company’s leadership team
Jan Aushadhi Diwas celebrations to generate awareness about the usages of generic medicines and benefits of Jan Aushadhi Pariyojana
With digitally available health records, individuals can avail paper-less health services under Ayushman Bharat Digital Mission (ABDM)
Sonowal exhorted young researchers and scientist to work on evidence based scientific research
Apixaban Tablets, 2.5 mg and 5 mg had annual sales of USD 18,876 mn in the United States (IQVIA MAT Dec. 2022).
The portfolio includes approximately 45 commercial products, four pipeline products and 40 approved non-marketed products, including a number of generic products focused on women’s health.
This combination medicine is used to treat high blood pressure (hypertension).
Receives Subject Expert Committee recommendation to bring new therapies of Pompe, ASMD to India
The company expects the GMP approval from Saudi Food and Drug Authority (SFDA) to soon pave the way for marketing authorizations from the largest market in the GCC region
Subscribe To Our Newsletter & Stay Updated